Files and links (2)
Published VersionCC BY V4.0, Open Access
Magazine article
The weight loss drug Mounjaro has been approved to treat sleep apnoea. How does it work?
The Conversation, Vol.12 June 2025
2025
Appears in Thompson Institute Research Collection
Abstract
Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a condition in which breathing stops and starts repeatedly during sleep.
The TGA has indicated Mounjaro can be used to treat moderate to severe obstructive sleep apnoea in adults with obesity (a body-mass index of 30 or above).
The United States Food and Drug Administration approved the same drug for sleep apnoea last year.
So how could this drug, most commonly used for weight management and conditions such as type 2 diabetes, help people with sleep apnoea?
Details
- Title
- The weight loss drug Mounjaro has been approved to treat sleep apnoea. How does it work?
- Authors
- Fatima Yaqoot - University of the Sunshine Coast, Queensland, Thompson InstituteNisreen Aouira - University of the Sunshine Coast, Queensland, Thompson Institute
- Publication details
- The Conversation, Vol.12 June 2025
- Publisher
- Conversation Media Group
- Date published
- 2025
- DOI
- 10.64628/AA.d9v7rwtxs
- ISSN
- 2201-5639
- Copyright note
- © The Conversation Media Group. This work is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
- Organisation Unit
- Thompson Institute
- Language
- English
- Record Identifier
- 991136701602621
- Output Type
- Magazine article
Metrics
255 File views/ downloads
362 Record Views